Contact Us

Human Cell-based

Drug Discovery Assets

discovered, validated and profiled using diseased and normal human cells as the discovery platform technologies

Research & Development Programs

Novel Chronically Acting ENaC inhibitor – ANT701 icon

Novel Chronically Acting ENaC Inhibitor – ANT701

This is a new type of epithelial sodium channel (ENaC) inhibitor that works through CFTR correction/ activation to lower ENaC cell surface expression. It is viable for all forms of polycystic kidney disease (PKD), cystic fibrosis (CF) , salt-sensitive hypertension and niche renal hypertensive disorders.

Novel STING Inhibitors icon

Novel STING Inhibitors

Hit-to-lead stimulator of interferon genes (STING) inhibitors. Viable for niche autoimmune diseases of the lung, kidney and skin, the “lupus” umbrella of autoimmune diseases and neurodegenerative diseases with chronic neuroinflammation component.

Novel Adiponectin Inducers – ADN12 and ADN18 icon

Novel Adiponectin Inducers – ADN12 and ADN18

These are lead and back-up lead small molecules, respectively, that stimulate human fat cells to produce and secrete the native adiponectin, a beneficial adipokine lost in diabetes and obesity. Viable for hypertriglyceridemia and for kidney injury and cardiac injury as secondary indications of diabetes and obesity.

About Us

AeroNeph Therapeutics, Inc. has emerged from the humanized drug discovery approach of its parent company, DiscoveryBioMed, Inc., and is continuing to develop lead and hit-to-lead small molecules for specific human disease indications and for human taste marketplaces.

Contact Us

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.